Management of betablocked patients after sustained virological response in hepatitis C cirrhosis

Table 2 Univariable analysis of factors associated factors with hepatic venous pressure gradient ≥ 12 mmHg

	< 12 mmHg (n = 13)	≥ 12 mmHg (n = 20)	P
Age (yr), median (P25-P75)	63 (55-70)	66 (59-73)	0.44
Males, n (%)	8 (61.5)	10 (50)	0.72
BMI > 25 kg/m2, n (%)	11 (84.6)	15 (75)	0.67
Baseline albumin (g/dL), median (P25-P75)	3.7 (3.4-3.8)	3.6 (3.2-3.8)	0.54
HVPG albumin (g/dL), median (P25-P75)	3.9 (3.8-4.3)	3.9 (3.8-4.1)	0.33
∆ Albumin (g/dL), median (P25-P75)	0.4 (0.1-0.8)	0.3 (0.1-0.5)	0.59
∆ Albumin (%), median (P25-P75)	11.8 (2.6-21.6)	9 (2.5-18.2)	0.58
Baseline platelets (× 103/μL), median (P25-P75)	88 (58-92)	58 (44-82)	0.19
HVPG platelets (× 103/μL), median (P25-P75)	79 (62-100)	74 (57-101)	0.59
∆ Platelets (× 103/μL), median (P25-P75)	5000 (-5000-17000)	6500 (-4000-17000)	0.89
∆ Platelets (%), median (P25-P75)	7.1 (-7.5-17.2)	10.9 (-8.4-28.3)	0.50
Baseline Child-Pugh A/B/C, n (%)	10 (76.9)/3 (23.1)/0 (0)	15 (75)/5 (25)/0 (0)	1
HVPG Child-Pugh A/B/C, n (%)	11 (84.6)/2 (15.4)/0 (0)	19 (95)/1 (5)/0 (0)	0.54
∆ Child Pugh	0 (-1-0)	-0.5 (-1-0)	0.59
Baseline MELD score, median (P25-P75)	10 (9-11)	10 (8-11)	0.58
HVPG MELD score, median (P25-P75)	9 (8-10)	10 (8-12)	0.50
∆ MELD score, median (P25-P75)	-1 (-1-0)	0 (-1-1.5)	0.045
Baseline TE (kPa), median (P25-P75)	21.1 (15.6-32)	27.7 (18.4-34.3)	0.39
HVPG TE (kPa), median (P25-P75)	20.3 (14.1-24.5)	23.3 (17.9-29.9)	0.31
∆ TE (kPa), median (P25-P75)	-6.2 (-10.7-2.1)	-4.3 (-7.8-3.4)	0.51
∆ TE (%), median (P25-P75)	-26.7 (-40.7-12.4)	-13.8 (-29.6-21.8)	0.69
Baseline ascites, n (%)	4 (30.8)	8 (40)	0.72
HVPG ascites, n (%)	1 (7.7)	2 (10)	1
BB prophylaxis, n (%)			0.13
Primary	13 (100)	16 (80)
Secondary	0	4 (20)

Baseline refers to data before direct-acting antivirals treatment. Hepatic venous pressure gradient refers to results on the day of the haemodynamic study. Baseline ascites or under diuretic treatment for previous ascites. BMI: Body mass index; HVPG: Hepatic venous pressure gradient; MELD: Model for End-Stage Liver Disease; TE: Transient elastography; BB: Betablockers; ∆: delta.